High-risk AML evidenced by a monoclonal antibody |
| |
| Authors: | S. Avnstr m,E. Ralfki r,N. E. Hansen,N. I. Nissen |
| |
| Affiliation: | Finsen Institute, Department of Medicine, Gentofte Hospital, Copenhagen, Denmark. |
| |
| Abstract: | A monoclonal antibody has been raised against a surface membrane antigen present on leukemic myeloblasts. In 52 consecutive patients with acute myeloid leukemia treated in a standardized fashion with intensive chemotherapy the immunologic subclass with respect to this antigen was correlated to the clinical outcome. We found the expression of this antigen to predict a poor prognosis, when measured as survival of CR-patients and as survival after 1st relapse. |
| |
| Keywords: | AML immunologic phenotype SA-1 prognosis |
|
|
